Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study.
Saved in:
| Title: | Cost-Effectiveness of Nirsevimab and Clesrovimab in Preventing Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Modeling Study. |
|---|---|
| Authors: | Yarnoff B; Evidera Inc., Wilmington, NC, USA. benjamin.yarnoff@thermofisher.com., Beuvelet M; Sanofi, Lyon, France., Soudani S; Sanofi, Lyon, France., Neary MP; Sanofi, Morristown, NJ, USA., Hodges EN; Sanofi, Morristown, NJ, USA., Chit A; Sanofi, Morristown, NJ, USA.; Lesie Dan Faculty of Pharmacy, University of Toronto, Toronto, Canada., Tribaldos M; Sanofi, Morristown, NJ, USA., Gabriel V; Sanofi, Morristown, NJ, USA., Musci R; Evidera Inc., Wilmington, NC, USA., Geurtsen J; Sanofi, Amsterdam, The Netherlands., Krilov LR; Pediatric Infectious Disease Consultant, Woodbury, NY, USA. |
| Source: | Infectious diseases and therapy [Infect Dis Ther] 2026 Apr; Vol. 15 (4), pp. 1047-1073. Date of Electronic Publication: 2026 Feb 26. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Adis Country of Publication: New Zealand NLM ID: 101634499 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8229 (Print) Linking ISSN: 21936382 NLM ISO Abbreviation: Infect Dis Ther Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2193-8229 |
|---|---|
| DOI: | 10.1007/s40121-026-01311-w |
